Does Rallies track congressional trades in REGN?

Yes. Rallies tracks politician and congressional stock disclosures for REGN, including reported purchases, sales, dates, owners, and trade amounts when available.

Is REGN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for REGN. It does not provide personalized investment advice.

REGN (Regeneron) Stock Analysis - Politician Trades

Regeneron (REGN) is a publicly traded Healthcare sector company. As of May 20, 2026, REGN trades at $643.47 with a market cap of $66.02B and a P/E ratio of 15.17. REGN moved +2.94% today. Year to date, REGN is -14.87%; over the trailing twelve months it is +5.69%. Its 52-week range spans $476.49 to $1,070.00. Analyst consensus is strong buy with an average price target of $884.89. Rallies surfaces REGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded REGN stock?

Recent politician trading activity in REGN includes disclosures from Julia Letlow, Rob Bresnahan, Byron Donalds, Rob Bresnahan, and Julie Johnson. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.

REGN Key Metrics

Key financial metrics for REGN
Metric	Value
Price	$643.47
Market Cap	$66.02B
P/E Ratio	15.17
EPS	$42.56
Dividend Yield	0.94%
52-Week High	$1,070.00
52-Week Low	$476.49
Volume	866.13K
Avg Volume	0
Revenue (TTM)	$14.92B
Net Income	$4.42B
Gross Margin	0.00%

Congressional Trades in REGN

Julia Letlow purchase REGN on Feb 12, 2026 (amount: $15.00K).
Rob Bresnahan purchase REGN on May 15, 2025 (amount: $15.00K).
Byron Donalds sale REGN on Apr 10, 2025 (amount: $15.00K) for Spouse.
Rob Bresnahan sale REGN on Feb 25, 2025 (amount: $15.00K).
Julie Johnson sale REGN on Feb 12, 2025 (amount: $15.00K) for Joint.

Latest REGN News

Itepekimab Cuts Exacerbations 27.1% in AERIFY-1 but Misses in AERIFY-2 — May 20, 2026
Regeneron Shares Plunge 12% After Melanoma Drug Combo Misses Trial, Losing $9 Billion — May 18, 2026
Regeneron Downgraded After Fianlimab Trial Misses PFS Threshold (p=0.0627) — May 18, 2026
Regeneron Shares Plunge 10% After Melanoma Trial Misses PFS Endpoint — May 18, 2026
Nasdaq’s Top Decile Stocks Post 164% Rally, Regeneron Gains 48% — May 9, 2026

Recent REGN Insider Trades

RYAN ARTHUR F sold 1 (~$771.32) on Apr 1, 2026.
RYAN ARTHUR F sold 3 (~$2.32K) on Apr 1, 2026.
RYAN ARTHUR F sold 8 (~$6.19K) on Apr 1, 2026.

REGN Analyst Consensus

19 analysts cover REGN: 0 strong buy, 15 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $884.89.

Common questions about REGN

Which politicians traded REGN stock?: Recent politician trading activity in REGN includes disclosures from Julia Letlow, Rob Bresnahan, Byron Donalds, Rob Bresnahan, and Julie Johnson. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in REGN?: Yes. Rallies tracks politician and congressional stock disclosures for REGN, including reported purchases, sales, dates, owners, and trade amounts when available.
Is REGN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for REGN. It does not provide personalized investment advice.